Alex has held a variety of editorial positions of increasing seniority on Scrip since joining the publication as a science reporter in 1998. Currently, she heads up the European editorial team coverage of commercial and R&D developments, while also writing news, analysis and features. Over the years, Alex has covered breakthroughs in R&D in a range of therapeutic areas, including infectious diseases, cardiology and cancer, and she enjoys interviewing key industry players and opinion leaders. Alex has a degree in Biochemistry and Microbiology from the University of Leeds and a keen interest in medical history.
Latest from Alexandra Shimmings
Sales of its novel COPD therapy in its first quarter on the market were more than double consensus estimates, and Verona sees more to come.
J&J acquired Taris in 2019 to gain access to TAR-200 and its drug delivery platform. Now, early clinical data suggest the product could delay or remove the need for cystectomy in several bladder cancer settings and the US healthcare giant is eyeing multi-blockbuster sales.
The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.
New Phase II data for the bispecific antibody show promise in colorectal cancer as the company seeks to spread the bispecific antibody’s wings. Phase III trials are on the horizon, where it will need to go up against standard of care.
AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.
Persistence has paid off for Incyte’s Zynyz in anal cancer with a Phase III win that should make up for a previous disappointment at the FDA and give a boost to the firm’s pipeline prospects for a post-Jakafi era.